Articles On Opthea (ASX:OPT)

Clinical-stage biopharmaceutical company Opthea (ASX:OPT) has announced that it is seeking to raise $80 million through a $10 million private placement and a $70 million entitlement offer.

Neuren’s US FDA approval for trofinetide has seen its share price boosted ~130% in past year   Eye disease specialist Opthea is undertaking two Phase 3 trials to treat Wet AMD with results due in mid 2024 Anteris Technologies is developing...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

Rumble Resources’s share price could double on zinc demand Opthea could rise more than 4x after Phase 3 completions Development Global has a portfolio of future facing metals   Wilsons says Rumble could double on zinc demand Wilsons Asset...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Highlights Imugene has advanced its ongoing Phase 1 MAST study with the first patients receiving dosing in the intratumoral (IT) and intravenous (IV) cohorts of CF33-hNIS in combination with Pembrolizumab. The study is focused on measu...

ASX 200 to rise on Tuesday ahead of the US CPI report Talk of extraterrestrial in US skies Manchester United reportedly for sale   The ASX 200 is poised to rise on Tuesday, tracking the rally in New York. At 8am AEDT, the ASX 200 Feb futu...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Jeremy Curnock Cook is the Managing Director and founder of BioScience Managers, a funds management business specialising in biotechnology investments in Australia and globally. He is also a director of Avita Medical Inc (ASX: AVH). Jeremy...

The long and short of 2022 is that it was a frustrating period for the Australian biotech sector but one with its fair share of rewards as the sector’s exponents furthered worthy drugs, diagnostics, devices and doodahs. For the sixth year,...

Lightning Minerals identifies multiple pegmatite intrusion outcrops at Dundas project Galan moves to 100pc ownership of the Green Bushes South Lithium Project Critical Resources’ recent assay results at Mavis Lake extends the current strik...

A decline in the stock market doesn’t mean you necessarily have to lose money Retail investors are not allowed to open a short-selling broker account in Australia But there is a handful of long-short and short-only funds available on the A...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

The Bendigo and Adelaide Bank Ltd (ASX: BEN) share price has suffered in August. It’s down by 16% in just two weeks. For a business as large as Bendigo Bank, that’s a significant fall in a short amount of time when the S&P/ASX 200...

The Beach Energy Ltd (ASX: BPT) share price plummeted 11% on Monday following the release of the company’s financial year 2022 earnings. The stock closed yesterday’s session at $1.645. Unfortunately, brokers shared in the market’s di...

Biopharmaceutical company Opthea (OPT) receives binding commitments for a US$90 million (A$127 million) two-tranche placement to institutional investors at $1.15 per share The clinical-stage healthcare stock has also secured up to US$170 m...

The Opthea Limited (ASX: OPT) share price closed 9.35% lower on Monday after the company announced details of a new share issue. Shares of the biopharmaceutical company finished the day at $1.26 each after opening at $1.39 this morning. Th...

The S&P/ASX 200 Index (ASX: XJO) is off to the races so far this Monday in a flying start to the week. At the time of writing, the ASX 200 has added a healthy 0.52% to back above 7,060 points. So let’s delve deeper into these gains an...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a solid gain. At the time of writing, the benchmark index is up 0.6% to 7,072.6 points. Four ASX shares that have failed to follow the market higher today ar...

What, exactly, is a CEO’s job? It seems like a simple question. Maybe you even have a simple answer for it. Yes, the buck stops at the big desk in the corner office. That’s true. So ‘everything’ might be a good answer. Or, if youâ€...

The Bluescope Steel Ltd (ASX: BSL) share price is higher on Monday after the company impressed investors with its FY22 results. Shares in the steel producer currently trade hands for $17.74 each, a 5.03% gain, after reaching a high of $18....

The jury’s still out on the outlook for the big four ASX banks, but there’s one alternative ASX share that might be looking too cheap to ignore, according to a leading broker. The bank share in question is the Judo Capital Holdings Ltd...

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. The stock market has...

Recent cap raising suggests biotechs may finally be making a comeback Mesblast annnounced a US$45m cap raise last week Today, Paradigm, Opthea, and Proteomics also announced fund raises Over the past year, the biotech sector has been caug...

The S&P/ASX 200 Materials Index (ASX: XMJ) is lifting 1.65% today, but three ASX mining shares are outperforming the index. The Belararox Ltd (ASX: BRX), Aurelia Metals Ltd (ASX: AMI) and Sarytogan Graphite Ltd (ASX: SGA) are all risi...

Opthea (ASX:OPT) has announced a non-dilutive financing transaction for up to US$170 million from investment funds working with Launch Therapeutics to progress the development of OPT-302 for wet age-related macular degeneration....

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX Powerplays. Several ASX health stocks have...

ASX 200 and small caps rise circa 1% Regional markets jump on strong leads, US inflation data Ragusa Metals: up 60% Local markets took off at the open, feeling a little of the excitement which took hold of Wall Street overnight. The bench...

Opthea (OPT) enters into a trading halt ahead of a capital raise There is currently no details on how much the company is aiming to raise however did mention of an upcoming funding agreement Under the halt, company shares will be paused un...

It’s a big day for ASX-listed Opthea, an eye therapies developer with a near $500 million market capitalisation. 

The Carlyle Group and its newly acquired life sciences arm Abingworth are chasing a four-bagger at Australian eye therapies developer Opthea.

What are the risks of investing in biotechs? How to value a biotech Top 10 crucial trials coming up for ASX biotechs in 2022 Risks of investing in biotechs Historical data shows that biotech is one the best sectors to put your money in ov...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

ShareCafeQueuing at the ATM: ASX small caps discover a handy source of funding ASX-listed small cap companies are flocking to the ATM for a ready source of cash, at a time and amount of their choosing. In this case, ATM does not refer to th...

May. Let’s start with US markets. Because May in the US started with the Dow making its biggest gain since 2020, followed within 24 hours by its biggest loss in 2022, perfectly summing up what kind of month May was to become. The US Fed rai...

Retinal biopharmaceutical company Opthea (OPT) presented its clinical data at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting The presentation was titled “Efficacy and Safety of OPT-302 in combination wi...

Opthea presents data at a renowned medical conference Osprey slashes workforce and is considering fresh cap raise Opthea presents data at conference Retinal diseases company Opthea Limited (ASX:OPT) rose by 1% today amongst a sea of reds....

  US stocks plunge in a broad based selloff Block Inc down 10% on NYSE as earnings disappoint ASX to open 1.5% lower this morning ASX to tumble as Wall Street dives The ASX 200 is set to open much lower this morning, following a broad sel...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

Opthea (ASX:OPT) has announced the appointment of Quinton Oswald and Dr Susan Orr to its board of directors.

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...